

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	CARDIEX LIMITED
<b>ABN</b>	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Craig Cooper
<b>Date of last notice</b>	25 October 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<u>C2 Ventures Pty Ltd</u> Craig Cooper is a co-beneficiary and controller of the securities held in this entity.  <u>CooperativeHealth LLC</u> Craig Cooper is the sole beneficiary and controller of the securities held in this entity.
<b>Date of change</b>	30 November 2021

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<u>Direct Interests</u> <ul style="list-style-type: none"> <li>68,000,000 Performance Rights</li> </ul> <u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> <li>197,242,010 FPO</li> <li>17,500,000 unlisted options at \$0.05 expiring 30 November 2021</li> <li>234,944 Convertible Notes with face value of \$1</li> <li>1,500,000 Options at \$0.05 expiring 26 February 2024</li> <li>4,420,455 CDXO at \$0.05 expiring 30 November 2021</li> </ul> <u>CooperativeHealth LLC</u> <ul style="list-style-type: none"> <li>36,000,000 Performance Rights</li> </ul>
<b>Class</b>	As above
<b>Number acquired</b>	<u>Direct Interest</u> <ul style="list-style-type: none"> <li>(a) 6,000,000 FPO</li> </ul> <u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> <li>(b) 17,500,000 FPO</li> <li>(c) 7,831,467 FPO</li> <li>(d) 2,240,455 FPO</li> </ul> <u>CooperativeHealth LLC</u> <ul style="list-style-type: none"> <li>(e) 12,000,000 FPO</li> </ul>
<b>Number disposed</b>	<u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> <li>(a) 17,500,000 unlisted options at \$0.05 expiring 30 November 2021</li> <li>(b) 234,944 Convertible Notes with face value of \$1</li> <li>(c) 2,420,455 CDXO converted</li> <li>(d) 2,000,000 CDXO transferred via off market transfer</li> </ul> <u>CooperativeHealth LLC</u> <ul style="list-style-type: none"> <li>(e) 12,000,000 Performance Rights exercised</li> <li>(f) 6,000,000 FPO transferred to Niall Cairns (or his nominee)</li> <li>(g) 6,000,000 FPO transferred to Craig Cooper's Direct Interest</li> <li>(h) 8,000,000 Performance Rights expired</li> </ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>In respect of the acquisitions of securities:</p> <ul style="list-style-type: none"> <li>(a) NIL</li> <li>(b) \$0.05 per share</li> <li>(c) \$0.03 per share</li> <li>(d) \$0.05 per share</li> <li>(e) NIL</li> </ul> <p>In respect of the disposals of securities:</p> <ul style="list-style-type: none"> <li>(a) N/A – conversion of unlisted options resulting in acquisition of FPO (see (b) above)</li> <li>(b) N/A – conversion of convertible note resulting in acquisition of FPO (see (c) above)</li> <li>(c) N/A – conversion of CDXO listed option resulting in acquisition of FPO (see (d) above)</li> <li>(d) Nil consideration received – off-market sale of CDXO listed options</li> <li>(e) Nil consideration received – exercise of vested Performance Rights</li> <li>(f) Nil consideration received – transfer of FPO received on conversion of vested Performance Rights to Carnethy Investments Pty Ltd (an entity controlled by Niall Cairns)</li> <li>(g) Nil consideration received – transfer of FPO received on conversion of vested Performance Rights from CooperativeHealth LLC to Craig Cooper</li> <li>(h) N/A – Performance rights cancelled on expiry</li> </ul>
<p><b>No. of securities held after change</b></p>	<p><u>Direct Interests</u></p> <ul style="list-style-type: none"> <li>• 68,000,000 Performance Rights</li> <li>• 6,000,000 FPO</li> </ul> <p><u>C2 Ventures Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 224,993,932 FPO</li> <li>• 1,500,000 Options at \$0.05 expiring 26 February 2024</li> </ul> <p><u>CooperativeHealth LLC</u></p> <ul style="list-style-type: none"> <li>• 16,000,000 Performance Rights</li> </ul>

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	In respect of the acquisitions of securities: (a) Transfer from Craig Cooper's indirect to direct interest (b) Exercise of unlisted options (c) 7,831,467 shares issued on conversion of Convertible Notes at \$0.03 per share (d) Exercise of CDXO (e) Vesting of performance rights  In respect of the disposals of securities: (a) conversion of unlisted options resulting in acquisition of FPO (b) conversion of convertible note resulting in acquisition of FPO (c) conversion of CDXO listed option resulting in acquisition of FPO (d) off-market sale of CDXO listed options (e) exercise of vested Performance Rights (f) off-market transfer of FPO received on conversion of vested Performance Rights to Carnethy Investments Pty Ltd (an entity controlled by Niall Cairns) (g) off-market transfer of FPO received on conversion of vested Performance Rights from CooperativeHealth LLC to Craig Cooper (h) Performance rights cancelled on expiry
---	---

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A as no interest in contracts
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	In respect of the off-market transfer of CDXO listed options, and the off-market transfers of FPO between CooperativeHealth LLC, Carnethy Investments Pty Ltd and Craig Cooper, the securities were not traded during a closed period.  All other transactions were not trades of securities so N/A in all other respects.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	CARDIEX LIMITED
<b>ABN</b>	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Niall Cairns
<b>Date of last notice</b>	25 October 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<u>C2 Ventures Pty Ltd</u> Niall Cairns is a co-beneficiary and controller of the securities held in this entity.  <u>Carnethy Evergreen Pty Ltd</u> Niall Cairns is the sole beneficiary and controller of the securities held in this entity.  <u>Carnethy Investments Pty Ltd</u> Niall Cairns is the sole beneficiary and controller of the securities held in this entity.
<b>Date of change</b>	30 November 2021

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. of securities held prior to change</b>	<u>Direct Interests</u> <ul style="list-style-type: none"> <li>68,000,000 Performance Rights</li> </ul> <u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> <li>197,242,010 FPO</li> <li>17,500,000 unlisted options at \$0.05 expiring 30 November 2021</li> <li>234,944 Convertible Notes with face value of \$1</li> <li>1,500,000 Options at \$0.05 expiring 26 February 2024</li> <li>4,420,455 CDXO at \$0.05 expiring 30 November 2021</li> </ul> <u>Carnethy Evergreen Pty Ltd</u> <ul style="list-style-type: none"> <li>4,600,000 FPO</li> </ul>
<b>Class</b>	As above
<b>Number acquired</b>	<u>Direct Interests</u> NIL <ul style="list-style-type: none"> <li><u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> <li>(a) 17,500,000 FPO</li> <li>(b) 7,831,467 FPO</li> <li>(c) 2,240,455 FPO</li> </ul> </li> <li><u>Carnethy Investments Pty Ltd</u> <ul style="list-style-type: none"> <li>(d) 6,000,000 FPO</li> </ul> </li> </ul>
<b>Number disposed</b>	<u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> <li>a) 17,500,000 unlisted options at \$0.05 expiring 30 November 2021</li> <li>b) 234,944 Convertible Notes with face value of \$1</li> <li>c) 2,420,455 CDXO converted</li> <li>d) 2,000,000 CDXO transferred via off market transfer</li> </ul>

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>In respect of the acquisitions of securities:</p> <ul style="list-style-type: none"> <li>(a) \$0.05 per share</li> <li>(b) \$0.03 per share</li> <li>(c) \$0.05 per share</li> <li>(d) NIL consideration paid</li> </ul> <p>In respect of the disposals of securities:</p> <ul style="list-style-type: none"> <li>(a) N/A – conversion of unlisted options resulting in acquisition of FPO (see (a) above)</li> <li>(b) N/A – conversion of convertible note resulting in acquisition of FPO (see (b) above)</li> <li>(c) N/A – conversion of CDXO listed option resulting in acquisition of FPO (see (c) above)</li> <li>(d) Nil consideration received – off-market sale of CDXO listed options</li> </ul>
<p><b>No. of securities held after change</b></p>	<p><u>Direct Interests</u></p> <ul style="list-style-type: none"> <li>• 68,000,000 Performance Rights</li> </ul> <p><u>C2 Ventures Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 224,993,932 FPO</li> <li>• 1,500,000 Options at \$0.05 expiring 26 February 2024</li> </ul> <p><u>Carnethy Evergreen Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 4,600,000 FPO</li> </ul> <p><u>Carnethy Investments Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 6,000,000 FPO</li> </ul>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>In respect of the acquisitions of securities:</p> <ul style="list-style-type: none"> <li>(a) Exercise of unlisted options</li> <li>(b) 7,831,467 FPO issued on conversion of Convertible Notes at \$0.03 per share</li> <li>(c) Exercise of CDXO</li> <li>(d) Off-market transfer of FPO from CooperativeHealth LLC</li> </ul> <p>In respect of the disposals of securities:</p> <ul style="list-style-type: none"> <li>(e) conversion of unlisted options resulting in acquisition of FPO</li> <li>(f) conversion of convertible note resulting in acquisition of FPO</li> <li>(g) conversion of CDXO listed option resulting in acquisition of FPO</li> <li>(h) off-market sale of CDXO listed options</li> </ul>

+ See chapter 19 for defined terms.



## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A as no interest in contracts.
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	In respect of the off-market transfer of CDXO listed options, and the off-market transfer of FPO from CooperativeHealth LLC, the securities were not traded during a closed period.  All other transactions were not trades of securities so N/A in all other respects.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	CARDIEX LIMITED
<b>ABN</b>	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Jarrod White
<b>Date of last notice</b>	14 January 2021

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<u>Traverse Accountants Pty Ltd</u> Jarrod White is the sole director of the securities held in this entity.
<b>Date of change</b>	30 November 2021
<b>No. of securities held prior to change</b>	<u>Direct Interests</u> 21,000,000 Performance Rights  <u>Traverse Accountants Pty Ltd</u> <ul style="list-style-type: none"><li>• 4,857,577 FPO</li><li>• 397,728 Options at \$0.05 expiring 30 November 2021</li><li>• 1,500,000 Options at \$0.05 expiring 15 January 2024</li></ul>
<b>Class</b>	As above

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	<u>Direct Interests</u> NIL  <u>Traverse Accountants Pty Ltd</u> (a) 397,728 FPO
<b>Number disposed</b>	<u>Traverse Accountants Pty Ltd</u> (b) 397,728 CDXO converted
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<u>Traverse Accountants</u> (a) \$0.05 per share (b) N/A – conversion of CDXO listed option resulting in acquisition of FPO (see (a) above)
<b>No. of securities held after change</b>	<u>Direct Interests</u> 21,000,000 Performance Rights  <u>Traverse Accountants Pty Ltd</u> <ul style="list-style-type: none"> <li>• 5,255,305 FPO</li> <li>• 1,500,000 Options at \$0.05 expiring 15 January 2024</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of CDXO

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A as no interest in contracts.
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

<sup>+</sup> See chapter 19 for defined terms.